Document:

<PAGE>

                                                                 EXHIBIT 10.13

                           MANAGING DIRECTOR CONTRACT

       The company Bruker AXS Analytical X-ray Systems GmbH referred to in the
       following as "Company," and Dr. Martin Haase, referred to in the
       following as "Director," hereby enter into the following Directorship
       Agreement effective July 1, 2000:

1.     SCOPE OF DUTIES / OBLIGATIONS

       The Director is entitled and obligated to conduct the business of the
       company and any subsidiaries belonging to the same to the best of his
       knowledge and ability in accordance with the provisions of law, the
       articles of incorporation, the instructions of the delegation of
       shareholders, and the bylaws.

       The shareholders reserve the right to appoint other directors.

       The Director shall represent the Company legally and extrajudicially in
       conjunction with a director, a holder of a power of attorney, or an
       authorized agent.

2.     BUSINESS TRANSACTIONS REQUIRING AUTHORIZATION

       Insofar as no other restrictions according to law or the articles of
       incorporation are to be observed, the Director shall require the prior
       authorization of the delegation of shareholders to perform the business
       transactions set forth in the bylaws for the directors.

3.     COMPENSATION

       As compensation for his activities, the Director shall receive:

       o      an annual base salary of DEM 200,000 to be paid in twelve equal
              installments at the end of each month.

       o      an annual bonus to be determined by the shareholders dependent on
              his personal performance and the profit or loss of the Company.
              This bonus shall consist of one income-dependent portion and one
              profit-dependent portion based upon the consolidated operating
              figures of the Bruxer AXS Group prepared according to US GAAP. The
              bonus shall come due at the end of the month following the month
              in which the operating results of the preceding fiscal year is
              determined. If the Director leaves the company of his own volition
              during the fiscal year, no bonus will be paid, with the exception
              of the semiannual income bonus. However, if the employment

<PAGE>

              relationship ends at the request of the employer, then the bonus
              accrued up to the date of termination shall be paid.

              o      The income-dependent bonus shall be 0.1% (one tenth of a
                     percent) of the consolidated revenue of the Bruker AXS
                     Group prepared according to US GAAP. It shall be paid
                     semiannually after the submission of the consolidated
                     operating figures (for the first 6 months) or after
                     submission of the audited annual report for the fiscal
                     year.

              o      For fiscal year 2000, the profit-dependent bonus shall be
                     1% (one percent) of the consolidated EBIT (operating EBIT)
                     of the Bruker AXS Group and shall be paid after submission
                     of the audited annual report. The percentage shall decrease
                     by 0.1% per year for the following fiscal years until it is
                     frozen at 0.5% beginning in fiscal year 2005 (see table).

                  -------------------------------------------------------------
                  Fiscal Year                EBIT-dependent bonus
                  -------------------------------------------------------------
                  2000                                     1.0%
                  -------------------------------------------------------------
                  2001                                     0.9%
                  -------------------------------------------------------------
                  2002                                     0.8%
                  -------------------------------------------------------------
                  2003                                     0.7%
                  -------------------------------------------------------------
                  2004                                     0.6%
                  -------------------------------------------------------------
                  2005                                     0.5%
                  -------------------------------------------------------------
                  2006 and following                       0.5%
                  -------------------------------------------------------------

       o      The Company reserves the right to review, and if necessary to
              adjust, the amounts of payments to the Director.

<PAGE>

4.     FURTHER CONDITIONS OF THE AGREEMENT

       The current provisions regarding

       -  Company car(s),

       -  Medical expenses / group insurance,

       -  Liability insurance, and

       -  Health resort cost allowance and preventive health care

       shall apply analogously in the context of this agreement (see Appendix 1,
       functional step 4). The currently valid version of the arrangements
       governing anniversaries and the establishment of term of service shall
       also analogously apply. The term of service spent at Siemens AG and AXS
       X-ray Systems GmbH shall be counted.

       In addition, the employment regulations of Bruker AXS GmbH shall apply
       for this Directorship Agreement, insofar as no other arrangement is
       explicitly agreed upon above.

5.     REIMBURSEMENT OF OUTLAYS / EXPENSES

       The Director shall be reimbursed for all expenses arising from business
       travel and other expenditures made in the interest of the Company. The
       currently valid company regulations shall apply for reimbursement of
       costs.

       Acknowledgment of expenses and payment shall be handled in a reciprocal
       fashion by the Director or the holder of a power of attorney.

6.     SECONDARY EMPLOYMENT

       For the duration of the contractual relationship, the Director agrees not
       to engage in commerce or to conduct business in the Company's line of
       business on his own behalf or on behalf of third parties without the
       consent of the delegation of shareholders. Furthermore, the director may
       not hold an interest in another company as a personally liable director
       without the consent of the delegation of shareholders.

       The compensated performance of secondary activities also requires the
       consent of the delegation of shareholders. This also includes the
       acceptance of memberships on supervisory boards and similar offices.

       If individual provisions of this agreement are or become void or
       ineffective, the validity of the remainder of the agreement shall remain
       unaffected. In the case of invalidity or

<PAGE>

       ineffectiveness of individual provisions of this agreement, provisions
       are to be adopted in their place that the parties of the agreement would
       have stipulated at the time of signing of the agreement upon objective
       analysis of the interests of both parties had they been aware of the
       invalidity or ineffectiveness of said provisions of the agreement.

       If the Director receives compensation of any kind as the member of a
       supervisory board, managing board, or board of directors or in any other
       capacity from a domestic or foreign holding company of the Company,
       except for the reimbursement of cash expenditures, this compensation may
       be counted as part of his income.

7.     PENSION AND SURVIVOR BENEFITS

       The Company shall enter into a separate agreement with the Director
       regarding pension and survivor benefits (see Appendix 2).

8.     VACATION

       Annual leave shall be 30 working days per calendar year.

9.     CONTINUED PAYMENT OF SALARY IN THE CASE OF SICKNESS OR DEATH

       In the case of inability to work as a result of illness, payment of the
       salary shall continue during the first 6 weeks.

       If the inability to work lasts longer, the employee shall,

       o      if he is covered by the statutory health insurance, receive a
              supplement to the cash sickness benefit for up to 72 weeks. The
              supplement shall be calculated such that, after deduction of
              applicable taxes, it corresponds to the difference between the
              cash sickness benefit of the company health insurance and his net
              salary.

       o      if he is not covered by the statutory health insurance, receive
              his last gross salary for an additional 72 weeks.

       Upon the death of an employee, the salary shall continue to be paid to
       the employee's spouse for the month of the employee's death and for 6
       months thereafter. The payment of survivor benefits shall be credited
       against such payments.

<PAGE>

10.    INVENTIONS, INTELLECTUAL PROPERTY RIGHTS, AND COPYRIGHTS

       The applicable legal and contractual provisions shall apply for
       inventions, patent applications, patents, and copyrights.

       If the employee produces copyright-protected works in conjunction with
       the fulfillment of his employment obligations or through the application
       of experience from or work with the company, the company shall, at the
       time of the works' creation, receive the exclusive, transferable right
       unlimited by place or time to use the protected works in any manner, and
       to reproduce, modify, sell, market, or distribute the same, without
       reference to the creator and without payment of extra compensation by the
       company for such activities.

       If the employee creates other copyright-protected works, he shall inform
       the company of the same if a use within the company appears to be
       possible. The company may acquire usage rights to such works in return
       for appropriate compensation. If the company has no interest in acquiring
       usage rights, the employee may use such works under consideration of the
       prohibition on competition pursuant to labor law.

11.    CONFIDENTIALITY

       The Director agrees to maintain strict confidentiality with regard to all
       business matters and procedures, in particular business and company
       secrets, which become known to him in the course of his activities. This
       shall apply for three years after any termination of this Agreement.

       Company documents of any kind may be used only in the interest of the
       Company and must be surrendered in all cases upon the request of the
       Company.

12.    NON-COMPETITION CLAUSE / ANTI-ENTICEMENT CLAUSE

       The Director agrees not to compete with the Company, either directly or
       indirectly, for a period of 12 months after any termination of the
       Employment Agreement, and in particular not to work with any company in
       the field of X-ray analysis (X-ray diffractometry and/or X-ray
       fluorescence spectrometry).

       In addition, the Director agrees not to entice any employee of Bruker AXS
       for his new employer for a period of 12 months following any termination.

<PAGE>

13.    DURATION OF THE AGREEMENT

       The contractual relationship shall last for an indeterminate period of
       time. It may be terminated at the end of a quarter by either party, with
       a notice period of six months, unless the observance of longer periods of
       notice is required by law.

       In the event of termination, the Director may be released from employment
       upon continued payment of his monthly salary and crediting of vacation.

       The legal provisions regarding the withdrawal of an appointment to the
       position of director shall not be affected hereby. In the event of
       termination, the withdrawal of an appointment to the position of
       director, or departure from the Company, the Director shall be obligated,
       upon the request of the Company, to resign from all offices and functions
       assigned to him within the context of his contractual relationship with
       the Company.

       The Agreement may be terminated without notice for good cause. For the
       Company, good cause shall exist in particular if the Director

       o      violates the non-competition or secondary employment clauses

       o      is in violation of this Agreement, the bylaws, or decisions or
              instructions of the delegation of shareholders.

12.    FINAL PROVISIONS

       Amendments or additions to this agreement must be made in writing.
       Compliance with this requirement for the written form can only be revoked
       in writing.

Karlsruhe, 6/29/2000

Company                                                       Director
Dr. Frank Laukien          Dr. Tony Keller                    Dr. Martin Haase

                      Appendix:                 Working conditions of employees
                                                above the regular pay scale
                                                Conditions for individual
                                                pension commitment

<PAGE>

                          ACKNOWLEDGMENT OF TRANSLATION

                                 August 14, 2001

         The undersigned officer of the Registrant hereby acknowledges on behalf
of the Registrant that the foregoing translation of the Managing Director
Contract between Bruker AXS Inc. and Martin Haase is a fair and accurate English
translation from German of the original executed agreement.

                                       BRUKER AXS INC.

                                       By: /s/ Martin Haase
                                           ---------------------------------
                                           Martin Haase, President and Chief
                                           Executive Officer<PAGE>

                                                                   Exhibit 10.15

                          STRATEGIC ALLIANCE AGREEMENT

         This Strategic Alliance Agreement ("Agreement") is made and entered
into as of October 2, 2001 by and between Bruker AXS Inc., a Delaware
corporation with its principal place of business in Madison, Wisconsin
("BAXS") and GeneFormatics Incorporated, a California corporation with its
principal place of business in San Diego, California ("GFI").

                                   WITNESSETH:

         WHEREAS, GFI is a leading structural proteomics company which intends
to conduct a round of financing with respect to GFI's Series C Preferred Stock
("Series C Financing") and to purchase from BAXS X-ray single crystal
diffraction ("XSCD") systems and related equipment ("XSCD Products");

         WHEREAS, BAXS is a leading XSCD company which desires to (i) sell to
GFI XSCD Products and to provide certain support and maintenance services
relating thereto, and (ii) make a [**] investment in GFI as part of the
Series C Financing ("BAXS Investment"); and

         WHEREAS, the parties desire to work together with respect to XSCD for
structural proteomics;

         NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants contained herein, the parties hereto hereby agree as follows:

         1.0 TECHNOLOGICAL COLLABORATION

         The parties shall work together in the following areas as may be
mutually agreed from time to time:

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS
EXHIBIT, WHICH PORTIONS HAVE BEEN OMITTED AND REPLACED WITH [**] AND FILED
SEPARATELY WITH THE COMMISSION.

<PAGE>

             1.1 GFI shall make a material investment in XSCD. GFI is in the
process of developing a specific XSCD strategy in conjunction with [**]of the
[**] and an exclusive consultant to GFI in the fields of structural genomics
and structural proteomics.

             1.2 In conjunction with developing such strategy, GFI shall work
with BAXS to incorporate BAXS' capabilities into such strategy. This shall
include, among other items, the following:

                 1.2.1 It is anticipated that GFI will initially [**]from
BAXS.

                 1.2.2 It is anticipated that, as part of a second phase, GFI
may expand its technology platforms for protein structure and function
discovery by [**].

             1.3 The XSCD lab at GFI may serve as a test site for future
capabilities.

             1.4 GFI may provide BAXS access to GFI's experimental protocols and
methods for automated crystallization and sample purification and preparation.

         2.0 INVESTMENT

             GFI intends to undergo a Series C Financing during the calendar
year 2001. BAXS shall make the BAXS Investment [**] as part of the Series C
Financing; provided, however, that such investment is required to be made by
BAXS only if GFI closes the Series C Financing during the 2001 calendar year
and GFI receives at least [**] in such Series C Financing (including the BAXS
Investment and the investments of any affiliates of BAXS). The BAXS

[**] Indicates that information has been omitted and filed separately with
the Commission pursuant to a request for confidential treatment.

                                       2
<PAGE>

Investment shall be comprised of [**] $500,000 of BAXS stock. The BAXS stock
shall be valued at (a) if the Series C Financing closes prior to September
15, 2001, $7.00 per share; and (b) if the Series C Financing closes after
September 15, 2001, (i) the fair market value thereof as determined by the
BAXS Board of Directors in agreement with GFI if the initial public offering
of BAXS has not yet been declared effective, or (ii) the average closing
price over the ten (10) NASDAQ trading days ending three (3) days prior to
the closing date of the Series C Financing, if the initial public offering of
BAXS has been declared effective. BAXS' completion of the BAXS Investment is
subject to the following:

             2.1 BAXS shall invest at a valuation and on terms and conditions no
less favorable than those provided to any other investor in GFI's Series C
Preferred Stock.

             2.2 If such Series C Financing is not closed on or before December
31, 2001, this Section 2.0 shall be of no further force or effect.

         3.0 SALE AND PURCHASE OF XSCD PRODUCTS

             Subject to closing of the BAXS Investment, GFI may from time to
time submit purchase orders for XSCD Products.

         4.0 PREFERRED CUSTOMER STATUS

             Given the parties' desire to create a strategic alliance
hereunder, BAXS shall sell XSCD Products and support to GFI at [**];
provided, however, GFI acknowledges that this also has to be a win-win
situation for BAXS, and that BAXS needs to receive its [**] on any purchases
of XSCD Products and support by GFI.

[**] Indicates that information has been omitted and filed separately with
the Commission pursuant to a request for confidential treatment.

                                       3
<PAGE>

         5.0 EXPENSES

             Each party shall be responsible for its own expenses in connection
with the execution of, and performance under, this Agreement.

         6.0 EXCLUSIVITY

             Subject to the terms and conditions contained herein and except for
XSCD Products not offered by BAXS, for the term of this Agreement, including any
extension thereof, BAXS shall be the sole and exclusive supplier of XSCD
Products to GFI.

         7.0 TERM

             7.1 The term of this Agreement shall commence as of the date of
this Agreement and continue for three (3) years thereafter, unless terminated
earlier as set forth herein. Upon mutual written agreement of the parties
prior to each expiration date, the term of this Agreement may be extended for
a series of successive [**] periods.

             7.2 Either party may terminate this Agreement effective immediately
and without liability upon written notice to the other party if any one of the
following events occurs: (a) the other party files a voluntary petition in
bankruptcy or otherwise seeks protection under any law for the protection of
debtors; (b) a proceeding is instituted against the other party under any
provision of the Federal Bankruptcy Code or equivalent legislation of a foreign
jurisdiction which is not dismissed within ninety (90) days; (c) the other party
is adjudicated bankrupt; (d) a court assumes jurisdiction of the assets of the
other party under a federal reorganization act or equivalent legislation of a
foreign jurisdiction; (e) a trustee or receiver is appointed by a court for all
or a substantial portion of the assets of the other party; (f) the other party
becomes insolvent, ceases or suspends

[**] Indicates that information has been omitted and filed separately with
the Commission pursuant to a request for confidential treatment.

                                       4
<PAGE>

business; (g) the other party makes an assignment of the majority of its assets
for the benefit of its creditors, or (h) the BAXS Investment is not made in
calendar year 2001.

             7.3 Either party may terminate this Agreement effective
immediately and without liability upon written notice to the other party if a
party breaches a material obligation hereunder and does not cure such breach
within [**] after receiving notice of such breach from the other party.

             7.4 The provisions of Sections 5, 7.4, 8, 10 and 11 shall survive
termination or expiration of this Agreement.

         8.0 CONFIDENTIALITY

             Each party shall itself, and shall cause its employees to, keep
confidential and refrain from using, except to the extent necessary to perform
the obligations set forth under this Agreement, all technology and all
confidential business and technical information disclosed to such party by the
other party. The foregoing shall not apply to such information that a party can
demonstrate (i) was known to such party before it was disclosed to such party,
(ii) was known to the public at the time of disclosure, or subsequently becomes
so known through no act or omission of such party, (iii) is received by such
party from a third party not under any obligation of confidentiality, (iv) is
owned by such party or (v) is developed by such party independently of any
disclosure hereunder. A party shall disclose such confidential information of
the other party only to those of its employees having a need to know and who
have agreed to be bound by duties of confidentiality no less protective than
those contained herein.

[**] Indicates that information has been omitted and filed separately with
the Commission pursuant to a request for confidential treatment.

                                       5
<PAGE>

         9.0 PUBLICITY

             Promptly upon the execution of this Agreement, the parties shall
issue a mutually agreeable joint press release which shall refer to the parties'
strategic relationship and BAXS' equity investment in GFI.

         10.0 OWNERSHIP

              10.1 This Agreement shall not give either party any ownership
interest in or rights to the patent rights, copyrights, trade secrets or any
other intellectual property rights ("IP Rights") of the other party, and all IP
Rights that are owned or controlled by a party at the commencement of this
Agreement shall remain under the ownership or control of such party.

              10.2 Each party shall own the entire right, title and interest in
any inventions, discoveries, improvements, works of authorship, computer
software, algorithms, or the like it may invent, make, author, or otherwise
develop under or in connection with this Agreement, including all IP Rights
relating thereto. Such party shall have the sole authority to determine what
intellectual property protection, if any, it desires to seek for such items.

              10.3 The parties [**] all inventions, discoveries,
improvements, works of authorship, computer software, algorithms, or the like
they [**] invent, make, author, or otherwise develop under or in connection
with this Agreement, and shall [**].

         11.0 MISCELLANEOUS PROVISIONS

              11.1 This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware.

[**] Indicates that information has been omitted and filed separately with
the Commission pursuant to a request for confidential treatment.

                                       6
<PAGE>

              11.2 Nothing contained herein shall be construed as constituting a
joint venture, partnership or other form of business organization. The parties
have entered into this Agreement solely as independent contractors, and neither
party shall have any authority to bind or commit the other party.

              11.3 All notices given hereunder shall be in writing, sent by
certified mail, return receipt requested, addressed as follows, provided that a
party may change its address for notices by notice thereof:

                  If to BAXS:     Bruker AXS Inc.
                                  5465 E. Cheryl Parkway
                                  Madison, WI 53711
                                  Attn.:  President

                  If to GFI:      GeneFormatics Incorporated
                                  5830 Oberlin Drive, Suite 200
                                  San Diego, CA 92121-3754
                                  Attn.:  President and Chief Executive Officer

              11.4 This Agreement shall be binding upon and inure to the benefit
of the parties hereto and their respective successors and assigns.

              11.5 This Agreement constitutes the entire agreement between the
parties concerning its subject matter and supersedes any prior or
contemporaneous agreements and understandings in connection therewith,
including, without limitation, that certain Non-Binding Letter of Intent for
Strategic Partnership in Structural Proteomics by and among GFI, BAXS and
certain affiliates of BAXS. This Agreement may be amended or waived only by a
written instrument executed by both parties.

                                       7
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first written above.

GENEFORMATICS INCORPORATED                 BRUKER AXS INC.

By: /s/ John P. Schmid                     By: /s/ Martin Haase
   --------------------------                  -------------------------------

Title: Chief Financial Officer             Title: President and
      -----------------------                       Chief Executive Officer
                                                  ----------------------------

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]